ISSN: 2167-1044
Mayur G Patel
India
Research Article
Efficacy and Safety of Escitalopram in First Episode of Major Depressive Disorder - A Tertiary Care Indian Center Experience
Author(s): Mayur G Patel, Vishal K Patel, Deepak S Tiwari, Viral R Shah, Dhruv S Patel and Nirav B Chanpa
Mayur G Patel, Vishal K Patel, Deepak S Tiwari, Viral R Shah, Dhruv S Patel and Nirav B Chanpa
Context: Major Depressive Disorder (MDD) is the most prevalent psychiatric illness and escitalopram is one of the most commonly used selective serotonin reuptake inhibitors (SSRI) for its treatment.
Aim: To study efficacy and safety of escitalopram in patients with first episode of MDD.
Materials and methods: This was a prospective, open label, eight weeks follow-up study. Eighty-four patients with first episode of MDD were selected using simple random sampling. Depression was diagnosed using DSM-5 diagnostic criteria for MDD. Montgomery-Asberg Depression Rating Scale (MADRS) was used to assess the severity of depression. Clinical Global Impression Severity (CGI-S) and Clinical Global Impression Improvement (CGI-I) were used to measure illness severity and global improvement. The Antidepressant Side-Effect Checklist (ASE.. View More»
DOI:
10.4172/2167-1044.1000324